MedTrace Logo

PSMA-PET Imaging for Advanced ACC/SDC

NCT03319641 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2018-05-30

No results posted yet for this study

Summary

Diagnostic study which evaluates the level of PSMA expression in patients with locally advanced, recurrent and/or metastatic ACC/SDC of ≥18 years old with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are eligible for 177Lu-PSMA therapy

Conditions

  • Salivary Gland Cancer
  • Adenoid Cystic Carcinoma
  • Salivary Duct Carcinoma

Interventions

DIAGNOSTIC_TEST

PSMA-PET/CT scan

perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC

Sponsors & Collaborators

  • Adenoid Cystic Carcinoma Research Foundation

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Carla ML van Herpen, MD, PhD · Radboud University Medical Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-25
Primary Completion
2018-05-14
Completion
2018-05-14

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03319641 on ClinicalTrials.gov